Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer

Journal of Clinical Oncology

Volumn 35, Issue 1, 2017, Pages 40-47

  Beer, Tomasz M ^a   Kwon, Eugene D ^b   Drake, Charles G ^c   Fizazi, Karim ^d   Logothetis, Christopher ^f   Gravis, Gwenaelle ^e   Ganju, Vinod ^g   Polikoff, Jonathan ^j   Saad, Fred ^k   Humanski, Piotr ^l   Piulats, Josep M ^m   Mella, Pablo Gonzalez ^o,p   Ng, Siobhan S ^h   Jaeger, Dirk ^q   Parnis, Francis X ⁱ   Franke, Fabio A ^r   Puente, Javier ⁿ   Carvajal, Roman ^s   Sengeløv, Lisa ^t   McHenry, M Brent ^u   Varma, Arvind ^v   Van Den Eertwegh, Alfonsus J ^w   Gerritsen, Winald ^x   more..

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e INSTITUT PAOLI CALMETTES   (France)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g MONASH UNIVERSITY   (Australia)

^h ST JOHN OF GOD HOSPITAL   (Australia)

ⁱ Adelaide Cancer Centre   (Australia)

^j KAISER PERMANENTE   (United States)

^k CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^l Niepubliczny Zaklad Opieki Zdrowotnej Specjalista   (Poland)

^m CATALAN INSTITUTE OF ONCOLOGY   (Spain)

ⁿ HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^o Instituto Oncológico   (Chile)

^p Instituto Oncológico Fundación Arturo López Pérez   (Chile)

^q UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^r Hospital de Caridade de Ijú   (Brazil)

^s Hospital Regional Valentin Gomez Farias   (Mexico)

^t GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^u BRISTOL MYERS SQUIBB   (United States)

^v DOCS Inc   (United States)

^w VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^x RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; IPILIMUMAB; PLACEBO; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; ASTHENIA; ASYMPTOMATIC DISEASE; CANCER CHEMOTHERAPY; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DOUBLE BLIND PROCEDURE; DRUG FATALITY; DRUG WITHDRAWAL; EXPLORATORY RESEARCH; FATIGUE; HEART ARREST; HEPATITIS; HUMAN; IMMUNOPATHOLOGY; KIDNEY FAILURE; LIVER TOXICITY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OVERALL SURVIVAL; PATIENT SAFETY; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT RESPONSE; VOMITING; BLOOD; BONE NEOPLASMS; CHEMICALLY INDUCED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MIDDLE AGED; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SECONDARY; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ASYMPTOMATIC DISEASES; BONE NEOPLASMS; DIARRHEA; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL RATE;

EID: 85009783306     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.69.1584     Document Type: Article

References (30)

1. Torre LA, Bray F, Siegel RL, et al: Global cancer statistics, 2012. CA Cancer J Clin 65:87-108, 2015
2. Scher HI, Fizazi K, Saad F, et al: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187-1197, 2012
3. Beer TM, Armstrong AJ, Rathkopf DE, et al: Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371:424-433, 2014
4. Fizazi K, Scher HI, Molina A, et al: Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13:983-992, 2012
5. Ryan CJ, Smith MR, Fizazi K, et al: Abiraterone acetate plus prednisone versus placebo plus pred-nisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): Final overall survival analysis of a randomised, doubleblind, placebo-controlled phase 3 study. Lancet Oncol 16:152-160, 2015
6. de Bono JS, Oudard S, Ozguroglu M, et al: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 376:1147-1154, 2010
7. Parker C, Nilsson S, Heinrich D, et al: Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213-223, 2013
8. Gillessen S, Omlin A, Attard G, et al: Management of patients with advanced prostate cancer: Recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol 26:1589-1604, 2015
9. Bronte V, Kasic T, Gri G, et al: Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med 201:1257-1268, 2005
10. Gannon PO, Poisson AO, Delvoye N, et al: Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods 348:9-17, 2009
11. Degl'Innocenti E, Grioni M, Boni A, et al: Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization. Eur J Immunol 35:66-75, 2005
12. Drake CG: Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 10: 580-593, 2010
13. Sobol I, Thompson RH, Dong H, et al: Immunotherapy in prostate cancer. Curr Urol Rep 16:34 2015
14. Kantoff PW, Higano CS, Shore ND, et al: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411-422, 2010
15. Fitzpatrick JM, Bellmunt J, Fizazi K, et al: Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel. Eur J Cancer 50: 1617-1627, 2014
16. Saad F, Miller K: Current and emerging immunotherapies for castration-resistant prostate cancer. Urology 85:976-986, 2015
17. Wolchok JD, Neyns B, Linette G, et al: Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11:155-164, 2010
18. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723
19. Romano E, Kusio-Kobialka M, Foukas PG, et al: Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci U S A 112:6140-6145, 2015
20. Prieto PA, Yang JC, Sherry RM, et al: CTLA-4 blockade with ipilimumab: Long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 18:2039-2047, 2012
21. Robert C, Thomas L, Bondarenko I, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517-2526, 2011
22. Weber JS, Kähler KC, Hauschild A: Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30: 2691-2697, 2012
23. Bristol-Myers Squibb: Yervoy (ipilimumab) package insert, 2015. http://packageinserts.bms.com/pi/pi-yervoy.pdf
24. Schadendorf D, Hodi FS, Robert C, et al: Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33:1889-1894, 2015
25. Maio M, Grob JJ, Aamdal S, et al: Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol 33: 1191-1196, 2015
26. Horvat TZ, Adel NG, Dang TO, et al: Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 33:3193-3198, 2015
27. Slovin SF, Higano CS, Hamid O, et al: Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: Results from an open-label, multicenter phase I/II study. Ann Oncol 24:1813-1821, 2013
28. Kwon ED, Drake CG, Scher HI, et al: Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 15: 700-712, 2014
29. Scher HI, Halabi S, Tannock I, et al: Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26: 1148-1159, 2008
30. Fizazi K, Drake C, Kwon E, et al: Updated overall survival (OS) from the phase 3 trial, CA184-043: Ipilimumab (ipi) vs placebo (pbo) in patients with post-docetaxel metastatic castration-resistant prostate cancer (mCRPC). Ann Oncol 25:iv259-iv260, 2014 (suppl 4)